"" Insider Sale at Camp4 Therapeutics
Camp4 Therapeutics Corp CEO Daniel Tardiff sold 1,738 shares of the company's common stock on August 19, 2026, worth $8,272 at $4.76 per share. The shares were previously acquired through the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan.
Recent Developments
The company has delivered a remarkable 202% return over the past year, with investors showing interest in its clinical-stage biotechnology endeavors. Analysts have upgraded its stock rating from Neutral to Overweight, with JPMorgan increasing its price target to $9.00. Chardan has also initiated coverage on CAMP4 with a buy rating and set a price target of $6.50.
Background
Camp4 Therapeutics maintains a strong balance sheet with more cash than debt and liquid assets exceeding short-term obligations. The company's prospects have garnered attention from investors, with several analysts expressing optimism about its potential.
